Product Description: Tenecteplase (TNK-tPA) is a modified tissue plasminogen activator. Tenecteplase is a recombinant human tissue plasminogen activator (rt-PA) that has been bioengineered to produce mutations in three gene loci. Tenecteplase (TNK-tPA) can be used in the study of acute ischemic stroke[1][2].
Applications: Metabolism-protein/nucleotide metabolism
Formula: N/A
References: [1]Kvistad CE, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022 Jun;21(6):511-519./[2]Thelengana A, et al. Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis[J]. Acta Neurologica Belgica, 2019, 119: 359-367.
CAS Number: 191588-94-0
Molecular Weight: N/A
Compound Purity: 95.0
Research Area: Metabolic Disease
Solubility: 10 mM in DMSO
Target: Others
English
Deutsch
